Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

SARS-CoV-2 Omicron has similar infectious viral load to Delta

by Medical Finance
in Coronavirus
Study: Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta, and Omicron. Image Credit: Dotted Yeti / Shutterstock.com
9
SHARES
105
VIEWS
Share on FacebookShare on Twitter

In a recent study published on the medRxiv* preprint server, researchers compare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pre-variants of concern (VOC) strains and the Delta VOC strain. To do this, the researchers compared ribonucleic acid (RNA) and infectious viral load (VL) in non-vaccinated individuals, as well as in vaccination breakthrough infections caused by the SARS-CoV-2 Delta and Omicron variants.

Study: Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta, and Omicron. Image Credit: Dotted Yeti / Shutterstock.com

Study: Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta, and Omicron. Image Credit: Dotted Yeti / Shutterstock.com

VL influences SARS-CoV-2 secondary transmission. Higher VL has been attributed, at least in part, to the emergence of Alpha and Delta VOCs.

Furthermore, with segments of the population having received vaccines, understanding VL in breakthrough infections post-vaccination is critical. Studies on the presence of infectious viruses by cell culture isolation are important, as RNA VL is a weak indicator for infectiousness.

About the study

In the current study, up to five days post-onset of symptoms (DPOS), the researchers examined viral load features in the upper respiratory tract (URT) of unvaccinated pre-VOC-infected coronavirus disease 2019 (COVID-19) participants, as well as vaccinated and unvaccinated Delta VOC-infected COVID-19 subjects. In this cohort, 384 samples were included, with 118 samples acquired from patients infected with the pre-VOC SARS-CoV-2 and 248 from patients infected with the Delta VOC.

A total of 121 of the Delta VOC-infected patients had been vaccinated twice prior to their infection, whereas 127 had not been vaccinated. The study also included 18 vaccinated people who had recently been infected with Omicron. Using quantitative real-time PCR (qRT-PCR) and a focus-forming assay, the researchers measured genome copies and infectious viral titers in SARS-CoV-2-positive nasopharyngeal swabs.

The researchers first examined whether RNA genome copies are a good predictor of infectious viral shedding. They then determined whether infectious viral loads in patient samples were related to patient age and gender.

Over the first five symptomatic days, the researchers compared genome copies and infectious viral levels in pre-VOC and Delta VOC samples from unvaccinated patients. They further evaluated genome copies and infectious viral loads in non-vaccinated and vaccinated patients infected with the Delta VOC throughout the first five days after infection to determine whether immunization had an effect on virus shedding.

The researchers also investigated infectious viral shedding in vaccinated patients infected with the novel VOC Omicron strain after it emerged. In nasopharyngeal swab samples obtained from 18 Omicron- and 17 Delta-infected patients, RNA, and infectious viral load levels were also compared.

Study findings

The results showed that unvaccinated Delta-infected individuals had a greater infectious viral load than pre-VOC infected patients and that vaccinated patients had a much lower infectious viral load. There was no difference in infectious viral load between Delta and Omicron breakthrough cases.

RNA genome copies in URT swab samples were only weakly linked with infectious virus shedding. In fact, the researchers discovered more RNA genome copies in the swabs of unvaccinated individuals infected with pre-VOC SARS-CoV-2 strains than the Delta VOC within the first five DPOS. At the same time, Delta VOC had greater infectious viral titers.

During the first five days after symptom onset, the researchers were able to show that infectious viral load, rather than RNA genome copies, is reduced in vaccinated Delta VOC patients. Furthermore, approximately 50% of transmissions for pre-VOC SARS-CoV-2 strains occur during this time frame, thereby indicating that a reduction in viral load could significantly contribute to a lower secondary attack rate.

According to the data, the higher transmissibility of the SARS-CoV-2 Omicron variant is not associated with the shedding of a larger number of infectious viral particles in vaccinated patients with equivalent RNA viral load and infectious virus shedding.

Quantitative infectious viral loads versus overall virus isolation success.

Quantitative infectious viral loads versus overall virus isolation success.

Limitations

Only samples with cycle threshold (Ct) values less than 27 were included and were obtained within the first five DPOS, but not later. As patients with low viral loads were not included, absolute counts on RNA copies are skewed toward larger viral loads.

Furthermore, the researchers were concentrated on infectious virus shedding. To this end, it was demonstrated that SARS-CoV-2 culture is unlikely to be successful from samples with higher Ct values and that the vast majority of secondary transmission occurs before five DPOS. However, this needs to be formally assessed in Omicron cases.

The researchers also did not have access to samples from Omicron-infected unvaccinated people due to the recent emergence of this strain. Finally, the researchers indicated that almost all of the patients in this study were vaccinated with messenger ribonucleic acid (mRNA) vaccines, which produce high neutralizing antibody titers but low mucosal antibodies. As a result, the findings do not apply to other vaccines, especially those used largely in low- and middle-income countries.

RNA viral load and infectious viral titers for unvaccinated vs. vaccinated individuals infected Delta (A) Genome copies (left panel) and infectious virus (right panel) for vaccinated and unvaccinated Delta infected patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. ***p=0·0005; ****p<0·0001. Genome copies (B) and infectious viral loads (C) measured for vaccinated and unvaccinated Delta infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.

RNA viral load and infectious viral titers for unvaccinated vs. vaccinated individuals infected Delta (A) Genome copies (left panel) and infectious virus (right panel) for vaccinated and unvaccinated Delta infected patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. ***p=0·0005; ****p<0·0001. Genome copies (B) and infectious viral loads (C) measured for vaccinated and unvaccinated Delta infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.

Conclusions

Taken together, the study results show that the Delta VOC has stronger infectivity but much lower infectivity and faster virus clearance in vaccinated individuals. Furthermore, the findings demonstrated that the Omicron and Delta VOCs have identical infectious viral loads. In addition to overall virus isolation performance, measuring viral loads can also provide superior insights into viral shedding dynamics in acute SARS-CoV-2 infection.

“We observed higher RNA genome copies in pre-VOC SARS-CoV-2 compared to Delta, but significantly higher IVTs in Delta infected individuals.”

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Increasing Antimicrobial Resistance in World Health Organization Eastern Mediterranean Region, 2017–2019. Image Credit: Fahroni/Shutterstock

Increasing trend of antimicrobial resistance in Eastern Mediterranean Region of World Health Organization

by Medical Finance
May 19, 2022
0

In a recent study published in the Emerging Infectious Diseases journal, researchers investigated the rising antimicrobial resistance (AMR) in the Eastern Mediterranean...

Study: The interaction of calcium ions with specific residues in the SARS-CoV fusion peptide and the regulation of viral infectivity. Image Credit: Juan Gaertner/Shutterstock

The relationship between highly conserved residues in the SARS CoV fusion peptide and their role in coordinating calcium binding for viral entry

by Medical Finance
May 19, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers evidenced the significance of calcium (Ca2+) in mediating the...

Study: Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19. Image Credit: plo/Shutterstock

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

by Medical Finance
May 19, 2022
0

In a recent study published in the Journal of Clinical Medicine, a team of researchers evaluated the effectiveness of regdanvimab...

Study: Oropharyngeal microbiome profiled at admission is predictive of the need for respiratory support among COVID-19 patients. Image Credit: crystal light / Shutterstock.com

Could oropharyngeal microflora predict COVID-19 patients’ need for respiratory support?

by Medical Finance
May 19, 2022
0

In a recent study published on the preprint server medRxiv*, researchers from the United States identify a subset of oropharyngeal...

Study: Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication. Image Credit: NIAID

Lower exosome component 2 expression protects against clinical SARS-CoV-2 infection

by Medical Finance
May 19, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that the lower expression of EXOSC2 human protein safeguards...

Study: Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses. Image Credit: ustas7777777 / Shutterstock.com

SARS-CoV-2 breakthrough infection leads to distinct neutralizing antibody response

by Medical Finance
May 19, 2022
0

Scientists have worked at an unprecedented speed to develop effective vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...

Next Post
Mutations in SARS-CoV-2 Omicron variant promote cell binding

Mutations in SARS-CoV-2 Omicron variant promote cell binding

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Study analyzes the impact of global trust in government due to the COVID-19 pandemic

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • ImageForNews 710327 16496351772217224
    The effect of unsuppressed HIV on T-cell response to COVID-19
  • Study: Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Image Credit: Jorieri / Shutterstock.com
    New, longest documented case of persistent acute SARS-CoV-2 infection
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply